Abstract
Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets
Author(s): Jarouche Marian, Ibrahim Martha, Pearson Jarryd, Low Mitchell, Rowe James
Issue: Jan/Feb 2020 - Volume 24, Number 1
Page(s): 77-82
Abstract
This study reports on the stability of United States Pharmacopeia-grade metronidazole powder and commercially available metronidazole tablets in two dye-free oral suspending vehicles, namely Oral Mix and Oral Mix Sugar-Free. Metronidazole at 50 mg/mL was prepared individually in Oral Mix and Oral Mix Sugar-Free suspension vehicles and placed in 50-mL amber polyethyleneterephthalate bottles and 3-mL amber plastic syringes and stored at 4°C or 25°C/60% relative humidity for 90 days. The solutions were analyzed at the time of preparation and at 7 days, 14 days, 30 days, 45 days, 60 days, 75 days, and 90 days, with the concentration of metronidazole measured by high-performance liquid chromatography with photodiode array detection. The oral solutions were also monitored for pH, homogeneity, color, and odor. Except for the Oral Mix suspension of metronidazole prepared from the United States Pharmacopeia-grade powder and from the commercial tablet, when stored in pre-filled syringes, all the other preparations were stable at 4°C or 25°C/60% relative humidity for 90 days, with the metronidazole remaining within ± 10% of the initial concentration. The pH, color, odor, and resuspendability remained essentially unchanged. Metronidazole in Oral Mix and Oral Mix Sugar-Free oral suspensions, compounded from United States Pharmacopeia-grade powder or commercially available tablets, are a suitable alternative as an extemporaneously prepared medication.
Related Keywords
- Beatrice Venkataya, MRes
- metronidazole
- antibiotic
- antimicrobial agent
- stability
- packaging
- storage
- oral suspensions
Related Categories
- PEER-REVIEWED
- STABILITIES, COMPATIBILITIES
- UNITED STATES PHARMACOPEIA CONVENTIONS
- INFECTIOUS DISEASE
Related Articles from IJPC
Issue/Page View/Buy |
Title/Author (Click for Abstract / Details / Purchase) |
---|---|
Jan/Feb 2020
Pg. 77-82
|
|
Mar/Apr 2021
Pg. 169-175
|
|
Nov/Dec 2008
Pg. 558-564
|
|
Jan/Feb 2021
Pg. 24-28
|
Author(s):
McElhiney Linda F
|
May/Jun 2015
Pg. 248-251
|
Author(s):
Donnelly Ronald F, Ying James
|
Jan/Feb 2021
Pg. 47
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2008
Pg. 170-173
|
|
Jul/Aug 2018
Pg. 320
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 94-98
|
Author(s):
Riepl Mike
|
May/Jun 2022
Pg. 238
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 57
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2013
Pg. 380-383
|
Author(s):
McElhiney Linda F
|
Sep/Oct 2012
Pg. 425
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 52
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 356
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2010
Pg. 69
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 430
|
Author(s):
Allen Loyd V Jr
|
May/Jun 1997
Pg. 200-205
|
|
Jan/Feb 1999
Pg. 34-35
|
Author(s):
Mason Dave
|
May/Jun 2005
Pg. 230
|
Author(s):
Allen Loyd V Jr
|